TGF-β signaling is one of the most versatile communication systems in the human body, governing everything from embryonic development to wound healing to immune regulation. The pathway centers on a family of secreted proteins called transforming growth factor-beta (TGF-β) that bind to receptors on the cell surface and trigger cascades of molecular events inside the cell. What makes TGF-β fascinating, and sometimes maddening for researchers trying to target it therapeutically, is that the same signal can produce opposite effects depending on the cell type, the tissue context, and the stage of a disease. In early-stage cancers, for instance, TGF-β acts as a tumor suppressor; in advanced cancers, it switches sides and drives tumor progression.
How the Signal Starts
TGF-β does not float around in your tissues ready to act. It is secreted in a latent form, locked inside a molecular “straitjacket” made of a protein shell called the latency-associated peptide (LAP). Before TGF-β can bind a receptor and do anything, that shell has to be physically opened. One of the most striking discoveries about TGF-β activation is that mechanical force can do the job. Integrins on the surface of cells grab the latent complex and pull on it, peeling the straitjacket apart at a force of roughly 40 piconewtons, which releases the active TGF-β molecule so it can reach nearby receptors.1Current Biology. Force-Induced Opening of the Latent TGF-β1 Straitjacket by Integrins This means that the stiffness and tension of the tissue itself helps control how much TGF-β is active at any given moment.
In epithelial cells lining the airways, for example, injury triggers the release of signaling molecules that cause the cells to contract using actin and myosin, the same molecular machinery used in muscle contraction. That contraction generates enough pull through a specific integrin to yank TGF-β free from its latent form.2PubMed Central. Epithelial cells utilize cortical actin/myosin to activate latent TGF-β through integrin α(v)β(6)-dependent physical force In tendons, physiological levels of tensile loading maintain a steady, controlled release of active TGF-β that keeps tendon cells healthy. A sudden loss of tension, like a tendon rupture, causes an uncontrolled flood of active TGF-β and massive cell death.3PubMed Central. Conversion of mechanical force into TGF-β-mediated biochemical signals So the pathway is not just chemically regulated; it is mechanically regulated in ways that tie signaling directly to the physical state of the tissue.
Receptors and the Assembly of the Signaling Complex
Once freed from its latent shell, active TGF-β binds to receptors on the cell surface. These receptors come in two flavors, called type I and type II, and they work as a team. The type II receptor grabs the ligand first, and that ligand-receptor pair then recruits the type I receptor into a four-part complex: two type II and two type I receptor molecules arranged symmetrically around a single TGF-β dimer.4PubMed Central. Structure of the ternary signaling complex of a TGF-beta superfamily member Crystal structures of these complexes have revealed that the type I receptor docks into a groove formed by the ligand and the type II receptor together, and that a flexible tail on the type II receptor acts as a tether to hold the type I receptor in place.5Molecular Cell. Crystal Structure of the TGF-β3:TβRII:TβRI Ternary Complex Complex Reveals a Novel Architecture for Receptor Assembly Disrupting that tether abolishes the ability of the complex to signal, which tells us the precise geometry of receptor assembly matters enormously.6PubMed. Cooperative assembly of TGF-beta superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding
When the type I and type II receptors come together around the ligand, the type II receptor phosphorylates (adds a chemical tag to) the type I receptor, switching it on. The activated type I receptor then passes the signal into the cell’s interior. The specifics of how the receptor complex is assembled explain why different members of the TGF-β superfamily, which includes bone morphogenetic proteins (BMPs) and activins, can trigger different responses despite using a similar overall blueprint. Slight differences in how each ligand positions its receptors change which downstream signals get fired.
Smad Signaling and the Non-Smad Routes
The best-understood route from the receptor to the nucleus runs through a family of proteins called Smads. The activated type I receptor grabs specific Smads, adds a phosphate tag to them, and sends them on their way. These activated Smads then pair up with a common partner called Smad4 and move into the nucleus, where they bind DNA and switch genes on or off.7Cold Spring Harbor Perspectives in Biology. TGF-β Signaling from Receptors to Smads Two main branches of Smad signaling exist: one runs through Smad2 and Smad3 (mainly activated by TGF-β and activin), and the other through Smad1, Smad5, and Smad8 (mainly activated by BMPs). These branches often end up regulating very different sets of genes.
Smads are not the whole story. TGF-β receptors also activate several other signaling routes that do not involve Smads at all. These non-Smad pathways include well-known signaling cascades such as the MAP kinase pathways (ERK, JNK, and p38), as well as PI3K/Akt signaling and small GTPases like Rho.8PubMed Central. Non-Smad Signaling Pathways of the TGF-β Family These parallel routes help explain why TGF-β can produce such a wide range of cellular responses. In one cell type, the Smad route may dominate, pushing cells toward growth arrest. In another, non-Smad signaling may take the lead, promoting cell migration. The balance between these routes is a big part of what makes TGF-β biology so context-dependent.
Built-In Brakes
A signal as powerful as TGF-β needs a shut-off mechanism, and the pathway has one built right in. When TGF-β activates its Smad cascade, one of the genes it turns on encodes Smad7, an inhibitory Smad that acts as a negative feedback brake. Smad7 works in two ways: it binds to the activated type I receptor and physically blocks the signaling Smads from getting phosphorylated, and it recruits enzymes called ubiquitin ligases that tag the receptor for destruction.9PubMed Central. Regulation of TGF-β signaling by Smad7 The result is that the signal dials itself down over time.
Smad7 also creates cross-talk between the two Smad branches. Because Smad7 can inhibit both the Smad2/3 branch and the Smad1/5/8 branch, activating one branch can dampen the other through shared Smad7 induction. Computational modeling of this network has shown that Smad7-mediated cross-talk is a major factor in shaping how cells respond differently to single versus multiple ligand stimulation.10PubMed Central. Computational modelling of Smad-mediated negative feedback and crosstalk in the TGF-β superfamily network This means the cell’s history of recent TGF-β superfamily exposure influences how it responds to the next signal, creating a kind of molecular memory.
The Cancer Paradox
Perhaps the most confounding feature of TGF-β signaling is its dual role in cancer. In normal epithelial cells and in early-stage tumors, TGF-β is a potent tumor suppressor. It halts cell division by blocking the molecular machinery that drives cells from one phase of the cell cycle to the next, and it can trigger programmed cell death in cells that should not be dividing.11Cancer Biology & Medicine. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer Cancers that lose the ability to respond to TGF-β, through mutations in receptors or Smads, remove one of the body’s built-in growth brakes.
But at some point during tumor evolution, the relationship flips. Advanced tumors not only become resistant to TGF-β’s growth-suppressing effects but actively co-opt the pathway to drive invasion, blood vessel formation, and spread to distant organs.12PubMed Central. TGF-β Family Signaling in Tumor Suppression and Cancer Progression One of the key mechanisms here is epithelial-mesenchymal transition (EMT), a process in which epithelial cells lose their adhesion to neighbors and acquire migratory, invasive properties. TGF-β is such a reliable inducer of EMT that simply adding it to epithelial cells in a lab dish is a standard way to trigger the process.13PubMed Central. TGF-beta-induced epithelial to mesenchymal transition To make matters more complex, EMT itself feeds back on TGF-β signaling: transcription factors like Snail and Slug, which drive EMT, promote the expression of TGF-β3, which then amplifies the EMT program further.14PubMed Central. Snail and Slug promote epithelial-mesenchymal transition through beta-catenin-T-cell factor-4-dependent expression of transforming growth factor-beta3
Immune Suppression in the Tumor Neighborhood
TGF-β does not only affect the tumor cells themselves. It reshapes the immune environment around the tumor in ways that help the cancer evade destruction. TGF-β suppresses the function of killer T cells and natural killer cells, the immune system’s main weapons against cancer. Blocking TGF-β in experimental models enhances these immune responses against tumors.15PubMed Central. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression More broadly, TGF-β serves as a central enforcer of immune tolerance, preventing immune cells from overreacting. That role is essential for avoiding autoimmune disease, but in the tumor microenvironment it becomes a liability, allowing cancer cells to hide from immune surveillance.16PubMed Central. Transforming Growth Factor-β Signaling in Immunity and Cancer
This immune-suppressive function has become highly relevant to the era of immunotherapy. Some patients who do not respond to checkpoint inhibitor drugs like anti-PD-1 or anti-PD-L1 appear to have tumors drenched in TGF-β, which keeps immune cells from infiltrating the tumor effectively. Combining TGF-β blockade with immunotherapy is an active area of clinical investigation.
Fibrosis and Wound Healing
Outside of cancer, TGF-β is best known as the master regulator of fibrosis, the excessive scarring that stiffens and damages organs. When you cut your skin, TGF-β helps orchestrate the repair process by activating fibroblasts (the cells that lay down structural tissue) and instructing them to produce collagen and other matrix proteins. It also converts fibroblasts into myofibroblasts, a more muscular cell type that contracts to close the wound.17PubMed Central. TGF-β signaling in fibrosis In healthy tissue repair, TGF-β switches off once the job is done. When it does not, chronic fibrosis develops.
This process is the central problem in conditions like pulmonary fibrosis, liver cirrhosis, and kidney fibrosis. TGF-β is persistently elevated in fibrotic tissues, driving continuous myofibroblast differentiation and excessive matrix buildup.18PubMed. TGFβ signaling and the control of myofibroblast differentiation: Implications for chronic inflammatory disorders The challenge for therapists is that you cannot simply block TGF-β systemically without undermining its essential roles in immune regulation, tissue maintenance, and tumor suppression. Strategies that target specific downstream mediators or specific contexts of TGF-β activity are therefore the focus of drug development.
Heart Disease and Connective Tissue Disorders
In the heart, TGF-β plays a similarly double-edged role. After a heart attack, TGF-β signaling helps resolve the initial inflammatory response and promotes the formation of scar tissue that replaces dead heart muscle. It upregulates collagen and fibronectin production and reduces the breakdown of the extracellular matrix by inducing enzymes that inhibit matrix-degrading proteins.19PubMed Central. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling Blocking TGF-β after the inflammatory phase of infarct healing reduces scar thickness but also changes the quality of the wound, increasing the number of myofibroblasts and altering the tissue architecture in ways that could compromise the repair.20Cardiovascular Research. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling
Over the longer term, TGF-β contributes to cardiac fibrosis, the gradual stiffening of the heart that underlies many forms of heart failure. It stimulates fibroblast proliferation and accelerates the production of extracellular matrix proteins in the injured heart.21PubMed Central. Pivotal Role of TGF-β/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players
Mutations in genes related to TGF-β signaling also underlie several inherited connective tissue disorders. Marfan syndrome, Loeys-Dietz syndrome, and Shprintzen-Goldberg syndrome all involve disrupted TGF-β signaling and can affect the skeleton, eyes, lungs, and cardiovascular system, particularly the aorta.22PubMed Central. TGF-β Signaling-Related Genes and Thoracic Aortic Aneurysms and Dissections Aortic aneurysm and dissection are life-threatening complications of these syndromes, and understanding the TGF-β signaling defect has been key to developing screening guidelines and evaluating drugs like losartan that may slow aortic dilation.
Cross-Talk with Other Signaling Pathways
TGF-β does not operate in isolation. Its signaling machinery is wired into other major cellular communication networks, and these interactions shape what TGF-β ultimately does in a given context. One well-studied example is the relationship between TGF-β and Wnt/β-catenin signaling. In the heart, TGF-β activates the Wnt pathway, and Wnt signaling in turn stabilizes the TGF-β/Smad response, creating a mutually reinforcing loop that promotes fibrotic changes.23PubMed. Crosstalk between the TGF-β and WNT signalling pathways during cardiac fibrogenesis In blood vessel smooth muscle cells, TGF-β/Smad3 signaling directly upregulates the expression of several Wnt ligands, leading to β-catenin stabilization and cell proliferation, a mechanism linked to the thickening of vessel walls after injury.24PubMed Central. A crosstalk between TGF-β/Smad3 and Wnt/β-catenin pathways promotes vascular smooth muscle cell proliferation
Another important interaction is between TGF-β and the Notch pathway, which controls cell fate decisions during development. The intracellular domain of the Notch receptor physically binds to Smad3, and the two cooperate to activate target genes that neither pathway could turn on as strongly alone.25PubMed Central. Cross-talk between the Notch and TGF-beta signaling pathways mediated by interaction of the Notch intracellular domain with Smad3 These partnerships help explain why the outcome of TGF-β signaling varies so dramatically between tissues: the same TGF-β signal produces different results depending on which other pathways are active in the cell at the time.
Stem Cells and Early Development
TGF-β family signaling is essential from the very earliest stages of life. In human embryonic stem cells, the TGF-β/activin/nodal branch of signaling is required to maintain pluripotency, the ability of a stem cell to become any cell type in the body.26PubMed. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells Block this signaling and stem cells begin to differentiate, losing their versatility.27Cell Research. TGF-β/activin/nodal signal regulates the fate of human embryonic stem cells This makes TGF-β signaling critical for anyone working in regenerative medicine or studying the fundamental biology of how a single fertilized egg gives rise to every tissue in the body.
Epigenetic and Metabolic Effects
TGF-β does not just flip gene switches through Smad proteins binding directly to DNA. It also reshapes the epigenetic landscape, the chemical modifications on DNA and the proteins that package it, which determine which genes are accessible and which are silenced. In kidney disease, for instance, TGF-β has been shown to activate an acetyltransferase that chemically modifies both histones (the spools that DNA wraps around) and specific transcription factors, opening up regions of the genome and sustaining the expression of disease-promoting small RNA molecules called microRNAs.28PubMed Central. TGF-β induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy In triple-negative breast cancer, TGF-β alters the expression of both long non-coding RNAs and microRNAs, with Smad2/3 binding directly to the promoters of several of these regulatory molecules.29Scientific Reports. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling These epigenetic effects mean TGF-β can create lasting changes in cell behavior that persist even after the original signal fades.
On the metabolic front, TGF-β is increasingly recognized as a driver of metabolic reprogramming in both cancer and fibrosis. In tumors, TGF-β alters how cells use glucose, amino acids, and lipids, reshaping the metabolic environment of the tumor in ways that support cancer cell growth and suppress immune function.30PubMed Central. TGF-β signaling in the tumor metabolic microenvironment and targeted therapies In lung fibroblasts, TGF-β activates a stress-response transcription factor called ATF4, which ramps up the production of enzymes in the serine-glycine synthesis pathway, funneling raw materials into the construction of new proteins and cellular building blocks needed for fibrotic tissue production.31American Journal of Respiratory Cell and Molecular Biology. TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation
Therapeutic Efforts Against TGF-β
Given TGF-β’s role in cancer progression, fibrosis, and immune evasion, there has been enormous interest in developing drugs that block the pathway. Numerous inhibitors have been designed, including small-molecule drugs that block the type I receptor’s kinase activity, antibodies that neutralize TGF-β ligands, and ligand traps that soak up TGF-β before it can reach receptors. Some of these have reached clinical trials, both as standalone treatments and in combination with other therapies like immune checkpoint inhibitors.32PubMed Central. Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
The central difficulty, as you might expect from everything above, is selectivity. A drug that blocks TGF-β everywhere in the body risks undermining immune tolerance (potentially triggering autoimmunity), impairing wound healing, and paradoxically removing TGF-β’s tumor-suppressive functions in tissues that still depend on them. Heart valve problems emerged as a toxicity concern in some early preclinical studies of systemic TGF-β inhibition. Newer strategies try to be more targeted: bifunctional molecules that direct TGF-β blockade to the tumor microenvironment, conditional approaches that only activate the inhibitor in certain tissues, or combinations that rely on short-term TGF-β blockade timed to maximize the window for immune attack. Progress has been real but incremental, reflecting the genuine complexity of a pathway that the body relies on for so many different functions.
An Ancient Signaling System
The TGF-β pathway is not a recent evolutionary invention. Genomic studies across dozens of species have shown that its core components emerged alongside the very first animals. The simplest known animal with a recognizable TGF-β signaling system is Trichoplax adhaerens, a tiny flat organism with no organs and only a handful of cell types, whose genome already encodes four Smad proteins and four receptors.33PubMed Central. Emergence, development and diversification of the TGF-beta signalling pathway within the animal kingdom The TGF-β ligands themselves appear to be among the most ancient cytokines characterized in both major branches of animal life, found in organisms ranging from mollusks to vertebrates.34PubMed. Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans In vertebrates specifically, studies tracing the molecular evolution of TGF-β genes back to lampreys, jawless fish that diverged from other vertebrates hundreds of millions of years ago, suggest that TGF-β family members are among the most ancestral immune regulators in the vertebrate lineage.35PubMed Central. Molecular Evolution of Transforming Growth Factor-β (TGF-β) Gene Family and the Functional Characterization of Lamprey TGF-β2 The extraordinary conservation of this pathway across such vast evolutionary distances underscores just how fundamental it is to animal biology, and helps explain why disrupting it has such far-reaching consequences.